Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Dearnaley

Showing results (41-50 of 85) with videos related to

Pageof 9
Sort By:
European Urology|January 9, 2018
Two-years Postradiotherapy Biopsies: Lessons from MRC RT01 TrialAntoine Kass-Iliyya, Gordana Jovic, Claire Murphy, et al.
Clinical and Translational Radiation Oncology|June 14, 2024
Weekly ultra-hypofractionated radiotherapy in localised prostate cancerNora Sundahl, Douglas Brand, Chris Parker, et al.
International Journal of Radiation Oncology, Biology, Physics|September 23, 2022
Standard and Hypofractionated Dose Escalation to Intraprostatic Tumor Nodules in Localized Prostate Cancer: 5-Year Efficacy and Toxicity in the DELINEATE TrialAlison C Tree, Laura Satchwell, Emma Alexander, et al.
International Journal of Radiation Oncology, Biology, Physics|June 8, 2017
Clinical Outcomes of Image Guided Adaptive Hypofractionated Weekly Radiation Therapy for Bladder Cancer in Patients Unsuitable for Radical TreatmentShaista Hafeez, Fiona McDonald, Susan Lalondrelle, et al.
Oncogene|June 9, 2004
Transcription factor E2F3 overexpressed in prostate cancer independently predicts clinical outcomeChristopher S Foster, Alison Falconer, Andrew R Dodson, et al.
BJU International|April 22, 2008
Early hormonal data from a multicentre phase II trial using transdermal oestrogen patches as first-line hormonal therapy in patients with locally advanced or metastatic prostate cancerRuth E Langley, Ian F Godsland, Howard Kynaston, et al.
The Lancet. Oncology|March 18, 2008
Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort studyRoy Vergis, Catherine M Corbishley, Andrew R Norman, et al.
Cancer Immunology, Immunotherapy : CII|June 26, 2012
DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8(+) T-cell responses and increases PSA doubling timeLindsey Chudley, Katy McCann, Ann Mander, et al.
International Journal of Radiation Oncology, Biology, Physics|June 25, 2015
Consensus Guidelines and Contouring Atlas for Pelvic Node Delineation in Prostate and Pelvic Node Intensity Modulated Radiation TherapyVictoria A Harris, John Staffurth, Olivia Naismith, et al.
International Journal of Radiation Oncology, Biology, Physics|January 12, 2022
Nonrandomized Comparison of Efficacy and Side Effects of Bicalutamide Compared With Luteinizing Hormone-Releasing Hormone (LHRH) Analogs in Combination With Radiation Therapy in the CHHiP TrialAlison Tree, Clare Griffin, Isabel Syndikus, et al.
Pageof 9

Showing results (41-50 of 85) with videos related to

Sort By:
Pageof 9
European Urology|January 9, 2018
Two-years Postradiotherapy Biopsies: Lessons from MRC RT01 TrialAntoine Kass-Iliyya, Gordana Jovic, Claire Murphy, et al.
Clinical and Translational Radiation Oncology|June 14, 2024
Weekly ultra-hypofractionated radiotherapy in localised prostate cancerNora Sundahl, Douglas Brand, Chris Parker, et al.
International Journal of Radiation Oncology, Biology, Physics|September 23, 2022
Standard and Hypofractionated Dose Escalation to Intraprostatic Tumor Nodules in Localized Prostate Cancer: 5-Year Efficacy and Toxicity in the DELINEATE TrialAlison C Tree, Laura Satchwell, Emma Alexander, et al.
International Journal of Radiation Oncology, Biology, Physics|June 8, 2017
Clinical Outcomes of Image Guided Adaptive Hypofractionated Weekly Radiation Therapy for Bladder Cancer in Patients Unsuitable for Radical TreatmentShaista Hafeez, Fiona McDonald, Susan Lalondrelle, et al.
Oncogene|June 9, 2004
Transcription factor E2F3 overexpressed in prostate cancer independently predicts clinical outcomeChristopher S Foster, Alison Falconer, Andrew R Dodson, et al.
BJU International|April 22, 2008
Early hormonal data from a multicentre phase II trial using transdermal oestrogen patches as first-line hormonal therapy in patients with locally advanced or metastatic prostate cancerRuth E Langley, Ian F Godsland, Howard Kynaston, et al.
The Lancet. Oncology|March 18, 2008
Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort studyRoy Vergis, Catherine M Corbishley, Andrew R Norman, et al.
Cancer Immunology, Immunotherapy : CII|June 26, 2012
DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8(+) T-cell responses and increases PSA doubling timeLindsey Chudley, Katy McCann, Ann Mander, et al.
International Journal of Radiation Oncology, Biology, Physics|June 25, 2015
Consensus Guidelines and Contouring Atlas for Pelvic Node Delineation in Prostate and Pelvic Node Intensity Modulated Radiation TherapyVictoria A Harris, John Staffurth, Olivia Naismith, et al.
International Journal of Radiation Oncology, Biology, Physics|January 12, 2022
Nonrandomized Comparison of Efficacy and Side Effects of Bicalutamide Compared With Luteinizing Hormone-Releasing Hormone (LHRH) Analogs in Combination With Radiation Therapy in the CHHiP TrialAlison Tree, Clare Griffin, Isabel Syndikus, et al.
Pageof 9